Pfizer endocrine/metabolic news
The Australian Competition and Consumer Commission (ACCC) initiated proceedings in the Federal Court of Australia against Pfizer for alleged misuse of market power and exclusive dealing relating to the supply of cholesterol drug Lipitor atorvastatin. The ACCC alleges that Pfizer offered significant discounts and rebates previously accrued on sales in exchange for pharmacies acquiring a minimum volume of up to a 12-month supply of Pfizer's generic version of atorvastatin. The ACCC alleges that Pfizer first made the offers prior to the loss of patent protection for Lipitor, when other generic suppliers were prevented from making competing offers. ACCC is seeking pecuniary penalties, declarations and costs. A hearing is slated for March 18. ...